PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Having wound down its healthcare business to pivot toward vision AI and autonomous driving, Alpha AI now faces its biggest crisis after a disclaimer of audit opinion for fiscal 2025 triggered a delisting cause and a trading halt.
In April 2026, the auditor issued a disclaimer of opinion on both separate and consolidated financial statements, triggering a delisting cause and a trading halt.
Revenue fell 37.2% year over year in 2025 following the suspension of the healthcare division, marking a fourth straight year of operating losses.
After a change of controlling shareholder to a civil partnership called AI Innovation Growth Equity in 2025, the company renamed itself Alpha AI and partnered with vision-AI firm AIMMO to pursue new businesses.
In June 2026 the company decided on a 10-for-1 share consolidation to adjust its float, and whether it has actually been completed and trading resumed needs to be verified via the latest filings.
Concerns over financial soundness persist as the company continues convertible-bond-funded investments in other firms, including a stake in hydrogen business NG W.
Alpha AI is a medical device maker listed on KOSDAQ in 2000 that historically operated two divisions: medical devices and healthcare products.
The medical division manufactures biocompatible metal implants for spine, fracture and joint surgery along with surgical instruments, carrying FDA certification for exports, and has maintained a leading domestic share in the trauma and spine segments.
The healthcare division sold thermal-stimulation devices, home medical devices, ionizers and health foods mainly through agency channels, and once accounted for a substantial share of revenue, but its agency-driven sales model hit its limits amid persistent losses, leading the company to suspend that division's operations in 2025.
In July 2025 the company changed its name from Alpha Nox to Alpha AI and formed a strategic partnership with vision-AI data platform firm AIMMO, declaring its entry into vision AI data markets including autonomous driving.
To that end, it added autonomous driving, vertical large language models, data center development and humanoid robotics to its stated business purposes.
Its governance subsequently shifted again as a civil-law partnership called AI Innovation Growth Equity became the controlling shareholder after securing a stake through a third-party private placement.
As part of its expansion drive, the company also acquired an 8.07% stake (2.75 million shares, KRW 5.5 billion) in hydrogen business NG W, funded through a convertible-bond substitute payment, alongside other outside equity investments.
Observers have noted that the overlap between the legacy medical device business and the new AI, hydrogen and real-estate-related investments remains limited.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩5.5B | -₩400M | −6.8% |
| 2025Q3 | ₩1.9B | -₩1.7B | −88.3% |
| 2025Q4 | ₩2.7B | -₩3.1B | −113.8% |
| 2026Q1 | ₩3.8B | -₩1.7B | −43.7% |
| 2026Q2 | ₩3.2B | -₩1.1B | −35.3% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩23.4B | -₩6B | -₩8.4B | −25.9% | −30.0% | 85.8% |
| 2023 | ₩26.9B | -₩14.1B | -₩20.2B | −52.6% | −110.2% | 178.2% |
| 2024 | ₩26.8B | -₩7.5B | -₩7.1B | −27.8% | −23.2% | 116.9% |
| 2025 | ₩16.8B | -₩5.7B | -₩6.1B | −34.0% | −19.8% | 135.0% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Consolidated revenue fluctuated from KRW 23.4 billion in 2022 to KRW 26.9 billion in 2023 and KRW 26.8 billion in 2024 before plunging 37.2% year over year to KRW 16.8 billion in 2025.
The company attributed the swings in revenue and profit to a shift toward profitability-focused sales in continuing operations and the effect of discontinued operations.
Operating loss widened from about KRW 6.0 billion in 2022 to KRW 14.1 billion in 2023 before gradually narrowing to KRW 7.5 billion in 2024 and KRW 5.7 billion in 2025, with the operating margin improving from -52.6% in 2023 to -34.0% in 2025.
Net loss attributable to owners widened to about KRW 20.2 billion in 2023 before narrowing to KRW 7.1 billion in 2024 and KRW 6.1 billion in 2025, though large losses have persisted throughout.
On a quarterly basis, after revenue of KRW 5.5 billion and an operating loss of KRW 0.4 billion in the second quarter of 2025, revenue collapsed to KRW 1.9 billion in the third quarter as the healthcare suspension took full effect, widening the operating loss to KRW 1.7 billion.
The fourth quarter posted the deepest loss, with revenue of KRW 2.7 billion and an operating loss of KRW 3.1 billion, and losses continued into the first quarter of 2026 (revenue KRW 3.8 billion, operating loss KRW 1.7 billion) and the second quarter (revenue KRW 3.2 billion, operating loss KRW 1.1 billion).
Total equity fell to about KRW 18.2 billion in 2023 before recovering to KRW 30.5 billion in 2024 and KRW 31.0 billion in 2025 via capital raises, but total liabilities also grew from KRW 24.4 billion in 2022 to KRW 41.8 billion in 2025, pushing the debt ratio from 85.8% to 135.0% over the period.
Operating cash flow has been negative for four consecutive years (roughly -KRW 5.5 billion, -KRW 9.0 billion, -KRW 7.2 billion and -KRW 9.6 billion from 2022 through 2025), reflecting a continued lack of internal cash generation.
The vision AI data and autonomous driving market that Alpha AI has declared its entry into is estimated at around KRW 430 trillion according to media reports, amid rising data demand from global automakers and robotics firms.
Partner AIMMO has been described as an established player in that market, having signed a five-year project agreement and a 15-year vendor license with BMW and conducted sensor-fusion data-building work for advanced driver-assistance systems (ADAS) in Germany.
Alpha AI itself, however, has not yet shown concrete collaboration results or revenue recognition from the AIMMO tie-up since the change of controlling shareholder and rebranding, and subsequent attention reportedly shifted to investments in hydrogen business NG W and real estate-related projects.
The legacy medical device business is regarded as holding a leading domestic share in the trauma and spine implant segments, but that market itself is mature and offers limited high growth potential.
Across the KOSDAQ market broadly, 54 KOSPI- and KOSDAQ-listed companies were found to have triggered delisting causes over inadequate audit opinions for fiscal 2025, with Alpha AI among them.
In this environment, pressure is mounting on capital-constrained small KOSDAQ companies to simultaneously execute a business pivot and restore accounting credibility.
Alpha AI's outside auditor, Taesung Accounting Corporation, issued a disclaimer of opinion on both the separate and consolidated financial statements in the fiscal 2025 audit report, triggering a delisting cause, and the KOSDAQ Market Division halted trading of the company's shares on April 7, 2026.
The company had to decide whether to file an objection within 15 business days of the delisting notice, by April 28, and if an objection was filed, the process would move to a review by the corporate examination committee to determine whether an improvement period would be granted.
Amid this, the company decided in June 2026 on a 10-for-1 share consolidation aimed at adjusting its float and stabilizing its share price, setting a listing date of August 21 for the consolidated new shares, which would raise the par value from KRW 500 to KRW 5,000.
Whether this consolidation and re-listing process was actually completed and trading resumed, and how it interacted with the delisting review, needs to be reconfirmed via the latest disclosures.
On the business side, the company is pursuing several new initiatives simultaneously, including the AIMMO vision-AI collaboration, hydrogen exposure through its NG W stake, and a real-estate partnership investment, but none has yet been shown in news reports to have generated revenue.
The company has stated in its filings that it expects the healthcare business suspension to lead to a narrower operating loss and an improved financial structure through a concentration of resources on its core business.
Alpha AI is a stock whose normal price discovery function has been significantly constrained for an extended period following the trading halt triggered by the April 2026 audit disclaimer.
Relative to net assets, the share price sits below book value per share, suggesting the market is taking a cautious stance on the company's going-concern status and the outcome of its new business initiatives.
Dividends have not been paid in recent years, reflecting a priority on repairing the balance sheet over shareholder returns amid persistent operating losses.
The recently decided 10-for-1 share consolidation is an attempt to adjust the float and par value to improve trading stability, rather than a factor that determines the direction of valuation metrics themselves.
Until the outcome of the delisting review and the normalization of the audit opinion are settled, any valuation comparison only carries meaning on the premise that the company continues as a going concern.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Cost savings emerged after the healthcare division's operations were suspended: cumulative revenue for the first three quarters of 2025 fell 5.5%, while the operating loss narrowed 46.0% and the net loss narrowed 14.7%. On a full-year basis, the 2025 operating loss also improved 33% year over year. This improvement, however, reflects a shrinking revenue base rather than growth-driven margin gains.
Alpha AI has formed a strategic partnership with AIMMO targeting the vision AI and autonomous driving data market, estimated at around KRW 430 trillion, and added autonomous driving, large language models, data centers and humanoid robotics to its business purposes.
Partner AIMMO is described as a company with a track record including a five-year project with BMW. Concrete revenue or order wins from this partnership, however, have not yet been confirmed.
The company has also diversified into an 8.07% stake (2.75 million shares, KRW 5.5 billion) in hydrogen business NG W, funded through a convertible-bond substitute payment. Such investments can be read as an attempt to build asset value beyond the legacy medical device business.
However, because the acquisition method uses a bond substitute rather than cash, it does not contribute to the company's actual cash position.
In April 2026 the auditor issued a disclaimer of opinion on both separate and consolidated financial statements, triggering a KOSDAQ delisting cause, and the exchange immediately halted trading of the shares.
The company had to decide within 15 business days whether to file an objection, and if the corporate examination committee does not recognize continued listing eligibility, delisting could follow. This represents a risk to the company's very survival, beyond ordinary earnings risk.
The suspension of the healthcare division caused revenue to plunge 37.2% year over year in 2025, extending a four-year streak of operating losses from 2022 through 2025. Although the operating margin has been improving, it remains stuck in double-digit negative territory.
With revenue continuing to decline, there is no evidence yet that new businesses have grown to a scale that could replace the lost revenue base.
The company changed controlling shareholders twice in about two years, and the market has raised concerns about the lack of overlap between its new businesses and its legacy operations.
During this period the company relied heavily on mezzanine financing (convertible bonds), and its cash and cash equivalents fell sharply from KRW 11.2 billion at the end of the first half of last year to KRW 2.1 billion at year-end.
The combination of frequent governance changes and reliance on convertible bonds raises the possibility of further dilution or funding strain ahead.
The fiscal 2025 audit report carried a disclaimer of opinion on both separate and consolidated financial statements, triggering a delisting cause and a trading halt.
Depending on the outcome of the objection process and the corporate examination committee's review, the company could be granted an improvement period or face confirmed delisting. If the audit opinion is not normalized in the following fiscal year either, continued listing itself could become impossible.
The company has expanded from its core medical device business into AI, hydrogen and real estate investments, but observers note that each new venture has minimal overlap with the legacy business. The vision-AI collaboration with AIMMO has also not yet been shown to have produced concrete revenue. Pursuing multiple new businesses simultaneously also risks spreading management focus too thin.
The debt ratio rose from 85.8% in 2022 to 135.0% in 2025, and operating cash flow has been negative for four consecutive years.
Cash and cash equivalents are also known to have declined sharply over a short period, while the company has repeatedly relied on convertible-bond funding and bond-substitute equity investments. Any further need for capital could lead to significant dilution for existing shareholders.
Investors should check whether the 10-for-1 share consolidation has actually been completed, whether trading has resumed, and any follow-up disclosures on the corporate examination committee review or improvement period.
Check whether third-quarter results show further improvement in revenue and profitability, and whether any AI- or new-business-related revenue appears for the first time.
Watch for follow-up disclosures on concrete collaboration outcomes with partner and investee firms such as AIMMO and NG W, including any stake sales or additional investments.
Whether the audit opinion for fiscal 2026 is normalized to an unqualified opinion is a key variable determining continued listing, and must be confirmed.
Alpha AI now faces its greatest risk yet—a disclaimer of audit opinion for fiscal 2025—amid the structural shrinkage of its core medical device business, the suspension of its healthcare division, and a series of pivots into AI, hydrogen and real estate.
The delisting cause and trading halt go beyond weak earnings, testing the company's very survival, with the outcome of the corporate examination committee's review standing as the key variable for its future direction.
Financial metrics showed a positive signal in a narrower operating margin following the healthcare suspension, but this reflects a much smaller revenue base rather than genuine improvement, and structural weaknesses—four straight years of operating losses and negative operating cash flow—remain unresolved.
New business pillars such as the AIMMO vision-AI collaboration and the NG W equity stake have yet to show evidence of translating into revenue or real synergy.
The decided 10-for-1 share consolidation is a measure aimed at adjusting the float and trading stability, but it remains a secondary factor until the more fundamental issues of the delisting review and audit opinion normalization are resolved.
Investors need to comprehensively examine three areas: accounting and listing risk, uncertainty over the business model transition, and deteriorating financial soundness.
Confirmation via future disclosures of whether trading resumes and what the next audit opinion will be will be the most critical clues for understanding this stock going forward.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.